Daniel C Pevear

Progenics Pharmaceuticals, Inc.

$8,250,851

Attributed

$8,250,851

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY2005–21

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

Funding mix

By agency

NIH$8,250,851 · 5

By mechanism

R44$7,337,216 · 3

R43$913,635 · 2

Top collaborators

No co-investigators on record.

Most similar at Progenics Pharmaceuticals, Inc.

Same institution · by research overlap

Glen Andrew Coburn$12,617,543

Others in their field

Top investigators on “Antiviral Agents”

Constance Ann Benson · University Of California, San Diego$209,152,068
Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
Judith S. Currier · University Of California Los Angeles$102,391,456
Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
Sharon A Nachman · Johns Hopkins University$77,262,665
John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403

Research focus

Antiviral AgentsScreeningBioavailableNational Institute Of Allergy And Infectious DiseasePharmaceutical PreparationsPropertyCell Culture TechniquesInhibitor/AntagonistLead SeriesLibrariesPathogenPharmaceutical ChemistryCulicidaePreventionLeadAlphavirusBiological AvailabilityEpidemicOralCandidate SelectionCaribbean RegionAmericasChikungunya VirusSeries